Amid Humanitarian Crisis in India, Merck Announces Voluntary Licensing Agreements With Five Indian Generics Manufacturers to Accelerate and Expand Global Access to Molnupiravir, an Investigational Oral Therapeutic for the Treatment of COVID-19

Merck, known as MSD outside of the United States and Canada, announced that the company has entered into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generics manufacturers. Read more.